Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-04-04
2010-10-05
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210
Reexamination Certificate
active
07807382
ABSTRACT:
The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
REFERENCES:
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5437865 (1995-08-01), Garin-Chesa et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 5811522 (1998-09-01), Wallace et al.
patent: 6090930 (2000-07-01), Wallace et al.
patent: 6146894 (2000-11-01), Nicolaides et al.
patent: 6217868 (2001-04-01), Wallace et al.
patent: 6391302 (2002-05-01), Wallace et al.
patent: 7615372 (2009-11-01), Nicolaides et al.
patent: 2006/0121541 (2006-06-01), Grasso et al.
patent: 2006/0239911 (2006-10-01), Nicolaides et al.
patent: 2007/0020271 (2007-01-01), Teicher et al.
patent: 0 239 400 (1994-08-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO94/11023 (1994-05-01), None
patent: 95/24483 (1995-09-01), None
patent: WO 95/24483 (1995-09-01), None
patent: WO 02/10217 (2002-02-01), None
patent: WO 02/54856 (2002-07-01), None
patent: WO2004/078942 (2004-09-01), None
patent: WO2005/086713 (2005-09-01), None
patent: WO 2006/017759 (2006-02-01), None
patent: WO 2006/060719 (2006-06-01), None
patent: WO 2006/116451 (2006-11-01), None
Becker et al. Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. The FASEB Journal. 2008;22:3059-3067.
Kuntz. Structure-based strategies for drug design and discovery. Science. 1992 257(5073):1078-1082.
Miller et al Ligand binding to proteins: the binding landscape model. Protein Sci. Oct. 1997;6(10):2166-79.
Asahara, T., et al., “Endothelial progenitor cells for postnatal vasculogenesis,” Am. J. Physiol. Cell Physiol., 2004, 287, C572-C579.
Bagley, R.G., et al., “Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells,” Cancer Res., 2003, 63, 5866-5873.
Banapour, B. et al., “Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus,” J. Immunol., 1987,139(12), 4027-4033.
Battle, T.E. et al., “TEM1/Endosialin participates in cell-matrix and cell-cell adhesion interactions,” abstract presented Apr. 16, 2007, Exhibit Hall, Los Angeles Convention Center.
Boerner, P., et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” J. Immunol., 1991, 147, 86-95.
Brady et al., “Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors,” J Neuropathol. Exp. Neurol., 2004, 63,1274-1283.
Bühring, H-.J., et al., “Expression of novel surface antigens on early hematopoietic cells,” Ann. N.Y. Acad. Sci., 1999, 872, 25-38.
Carson-Walter, E.B., et al., “Cell surface tumor endothelial markers are conserved in mice and humans,” Cancer Res., 2001, 61, 6649-6655.
Chothia, C. et al., “Canonical Structures for the Hypervariable Regions of Immunglobulins,” J. Mol. Biol., 1987, 196:901-17.
Christian, S. et al., “Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium,” J. Biol. Chem., 2001, 276, 48588-48595.
Christian S., et al., “Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium,” J. Biol. Chem., 2001, 276(10), 7408-7414.
Cole, S.P.C., et al., “The EBV-hybridoma technique and its application to human lung cancer,”Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985, 77-96.
Conejo-Garcia, J.R., et al., “Vascular leukocytes contribute to tumor vascularization,” Blood, 2005, 105(2), 679-681.
Das, A., et al., “Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition,” Prog. Retin. Eye Res., 2003, 22(6), 721-748.
Davies et al., “Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer,” Clin. Exp. Metastasis, 2004, 21:31-37.
Dhanabal, “Anti-angiogenic therapy as a cancer treatment paradigm,” Curr. Med. Chem. Anti-Canc. Agents, 2005, 5, 115-130.
Dillman, R.O., “Monoclonal Antibodies for Treating Cancer,” Ann. Internal Med., 1989, 111, 592-603.
Dolznig et al., “Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin,” Cancer Immun., 2005, 5:10.
Florell, S.R., et al., “Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol,” Mod. Pathol., 2001, 14(2), 116-128.
Foote, J. et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J. Mol. Biol., 1992, 224:487-99.
Galiano, R.D., et al., “Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells,” Am. J. Pathol., 2004, 164(6), 1935-1947.
Garmestani, K. et al., “Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides,” Nucl. Med. Biol., 2001, 28, 409-418.
GenBank Accession No. AF279142, “Homo sapienstumor endothelial marker 1 precursor (TEM1) mRAN, complete cds,” Aug. 23, 2000.
Hanahan, D., et al., “The hallmarks of cancer,” Cell, 2000, 100(1), 57-70.
Homandberg, “Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments,” Front Biosci., 1999, 4:D713-730.
Huang, C., et al., “Construction of representative immunoglobulin variable region cDNA libraries from human peripheral blood lymphocytes without in vitro stimulation,” J. Immunol. Methods, 1991, 141, 227-236.
Huber et al., “Expression of stromal cell markers in distinct compartments of human skin cancers,” J. Cutan. Pathol., 2006, 33:145-155.
Hynes, R.O., “Integrins: Bidirectional, Allosteric Signaling Machines,” Cell, 2002, 110:673.
Jones, P.T., et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 1986, 321, 522-525.
Kala, M. et al., “Phage Displayed Antibodies to Heat Stable Alkaline Phosphatase: Framework Region as a Determinant of Specificity,” J. Biochem., 2002, 132:535-41.
Khazaeli, M.B., et al., “Human immune response to monoclonal antibodies,” J. of Immunother., 1994, 15, 42-52.
Kikuchi, Y. et al., “Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma,” Leuk. Res., 2005, 29, 445-450.
Köhler, G., et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 1975, 256, 495-497.
Kozbor, D., et al., “The production of monoclonal antibodies from human lymphocytes,” Immunol. Today, 1983, 4(3), 72-79.
Kreitman, R.J., et al., “Immunotoxins for targeted cancer therapy,” Adv. Drug Del. Rev., 1998, 31, 53-88.
Kurosawa, N., et al., “Genomic analysis of a murine cell-surface sialomucin, MGC-24/CD163,” Eur. J. Biochem., 1999, 265, 466-472.
Kusano, A. et al., “Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies,” Anticancer Res.,1993
Grasso Luigi
Nicolaides Nicholas C.
Sass Philip M.
Tomkowicz Brian
Zhou Yuhong
Haddad Maher M
Morphotek Inc.
Woodcock & Washburn LLP
LandOfFree
Methods for inhibiting the binding of endosialin to ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting the binding of endosialin to ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting the binding of endosialin to ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4174270